SCHEMBL924384

SCHEMBL924384

O=S(=O)(Cl)c1ccc(Oc2ccccc2)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.56
MMP1 P03956 1/20 0.56
MMP2 P08253 1/20 0.56
MMP13 P45452 1/20 0.56
MMP14 P50281 1/20 0.56
ADAMTS5 Q9UNA0 1/20 0.56
ALDH1A1 P00352 4/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
BCL2L1 Q07817 1/20 0.47
MCL1 Q07820 1/20 0.47
UCHL1 P09936 1/20 0.46
USP30 Q70CQ3 1/20 0.46
SOS1 Q07889 1/20 0.43
LTA4H P09960 1/20 0.43
HTT P42858 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
KDM4E B2RXH2 2/20 0.41
USP2 O75604 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26131622 0.84 HSPB1 (0.56) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL12327379 0.83 ADAMTS4 (0.56) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL4001719 0.83 ADAMTS4 (0.59) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL14075565 0.83 SOS1 (0.61) ADAMTS4MMP1MMP2MMP13MMP14
Hydrochloric Acid SCHEMBL28163868 0.82 ADAMTS4 (0.58) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL10833881 0.81 ADAMTS4 (0.53) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL20325535 0.80 LIPE (0.48) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL31244 0.80 SOS1 (0.64) MMP1MMP2MMP13MMP14ALDH1A1
SCHEMBL9536733 0.80 SOS1 (0.64) MMP1MMP2MMP13MMP14ALDH1A1
SCHEMBL8429606 0.80 ADAMTS4 (0.52) ADAMTS4MMP1MMP2MMP13MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100310544-A1 COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES MEDEVICE S.P.A. (IT) 2010-12-09 US claimed
EP-2227083-A1 COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES Medevice S.P.A. (IT) 2010-09-15 EP claimed
WO-2009069022-A1 COMPOSITION COMPRISING CALCIUM IONS AND AT LEAST ONE PROTEOLYTIC ENZYME FOR USE IN THE IN VITRO AND IN VIVO REGENERATION OF CUTANEOUS AND CONNECTIVE TISSUES MEDEVICE S.P.A. (IT) 2009-06-04 WO claimed
US-10800730-B2 Complex and structurally diverse compounds THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2020-10-13 US disclosed
US-20190152891-A1 COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-05-23 US disclosed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 US disclosed
US-10081592-B2 Complex and structurally diverse compounds THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2018-09-25 US disclosed
US-10035811-B2 Derivatives of 1-amino-2-cyclobutylethylboronic acid MILLENNIUM PHARMACEUTICALS, INC. (US) 2018-07-31 US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 US disclosed
US-20170349611-A1 DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-07 US disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 ADAMTS4 2925/4885MMP1 3483/4885MMP2 2085/4885
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL ADAMTS4 226/4885MMP1 636/4885MMP2 149/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 ADAMTS4 2925/4885MMP1 3483/4885MMP2 2085/4885
US-10081592-B2 Complex and structurally diverse compounds CYP11A1, LSS, CYP17A1 ADAMTS4 3843/4885MMP1 4724/4885MMP2 4509/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL ADAMTS4 192/4885MMP1 589/4885MMP2 151/4885
US-10035811-B2 Derivatives of 1-amino-2-cyclobutylethylboronic acid PSMB6, PSMB5, PSMB1 ADAMTS4 3993/4885MMP1 4109/4885MMP2 4508/4885
US-20170349611-A1 DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID PSMB6, PSMB5, PSMB1 ADAMTS4 3993/4885MMP1 4109/4885MMP2 4508/4885
US-10800730-B2 Complex and structurally diverse compounds CYP11A1, LSS, CYP17A1 ADAMTS4 3485/4885MMP1 4714/4885MMP2 4485/4885
US-20190152891-A1 COMPLEX AND STRUCTURALLY DIVERSE COMPOUNDS CYP11A1, LSS, CYP17A1 ADAMTS4 3485/4885MMP1 4714/4885MMP2 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.